EUVIMEDEUVIMED entdecken
Systematische Übersicht

Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005

Thainá Toledo iD, Vanessa G Oliveira iD, Vitória Berg Cattani iD, Karine Seba iD, Valdilea Gonçalves Veloso iD, Beatriz Grinsztejn iD, Sandra Wagner Cardoso iD, Thiago S Torres iD, Rita Estrela iD

Clinical Pharmacokinetics · 2024

DOI: 10.1007/s40262-024-01441-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Thainá Toledo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sérgio Arouca National School of Public Health ENSP Fiocruz, Rio de Janeiro, RJ, Brazil. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit nennt 102 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Programa Jovens Pesquisadores - INI/Fiocruz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Advances in antiretroviral therapy led to an increase in life expectancy among people living with human immunodeficiency virus (HIV). As aging is characterized by several physiological changes that can influence pharmacokinetics (PK), this systematic review aims to describe the impact of aging on the PK of antiretrovirals (ARV) approved by the Food and Drug Administration (FDA) before 2005. METHODS: Searches were performed in BVS, EMBASE, and PubMed databases for publications until June 2024. Peer-reviewed published studies were included if they met the following criteria: adults (≥ 18 years) living with HIV; reporting at least one PK parameter or plasma concentration of any ARV approved by the US FDA before 2005 and still used in the clinic: lamivudine (3TC), emtricitabine (FTC), tenofovir disoproxil fumarate (TDF), abacavir (ABC), zidovudine (ZDV), efavirenz (EFV), nevirapine (NVP), atazanavir (ATV), lopinavir (LPV), ritonavir (RTV), tipranavir (TPV), and fosamprenavir (FPV); PK parameters stratified per age group as young (aged 18-49 years) or older (age ≥ 50 years) adults; and manuscripts published in English, Portuguese, or Spanish. All studies were evaluated for risk of bias. The review protocol was registered in the PROSPERO database (registration no. CRD42023463092). RESULTS: Among 106 studies included, only 22 evaluated the PK of participants aged 50 years or older and only 5 studies compared the PK between young and older adults for ATV, RTV, EFV, and 3TC. Our analysis revealed an increase in minimal concentration (Cmin) values for LPV, RTV, and ATV in older adults. While increased values of the area under the curve (AUC) and maximum concentration (Cmax) were observed in older adults using ATV, 3TC, and FTC, no differences in PK were apparent between young and older adults for ABC and EFV, with no estimation possible for ZDV. CONCLUSION: Exposure to 3TC, TDF, FTC, ATV, LPV, and RTV increases with age, while exposure to ABC and EFV appears to be unaffected. Despite the large quantity of data on PK in young adults, there is still a gap in knowledge about the effects of aging on the PK of these ARVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHumansAgedMiddle AgedUnited StatesAdultDrug ApprovalAgingAge FactorsAnti-Retroviral AgentsUnited States Food and Drug AdministrationMale

Substanzen

Anti-HIV AgentsAnti-Retroviral Agents

Autor:innen und Institutionen

  • Sérgio Arouca National School of Public Health ENSP Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Evandro Chagas National Institute of Infectious Diseases INI Fiocruz, Rio de Janeiro, Brazil.
  • Faculty of Pharmacy, Fluminense Federal University, Rio de Janeiro, Brazil.
  • Sérgio Arouca National School of Public Health ENSP Fiocruz, Rio de Janeiro, RJ, Brazil. rita.estrela@ini.fiocruz.br.
  • Evandro Chagas National Institute of Infectious Diseases INI Fiocruz, Rio de Janeiro, Brazil. rita.estrela@ini.fiocruz.br.
  • Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. rita.estrela@ini.fiocruz.br.

ORCID-Profile: Thainá Toledo, Vanessa G Oliveira, Vitória Berg Cattani, Karine Seba, Valdilea Gonçalves Veloso, Beatriz Grinsztejn, Sandra Wagner Cardoso, Thiago S Torres, Rita Estrela

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Programa Jovens Pesquisadores - INI/Fiocruz
  • Programa Jovens Pesquisadores − INI/Fiocruz

Zitieren

APA

Toledo, T., Oliveira, V. G., Cattani, V. B., Seba, K., Veloso, V. G., Grinsztejn, B., Cardoso, S. W., Torres, T. S., & Estrela, R. (2024). Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01441-9

Vancouver

Toledo T, Oliveira VG, Cattani VB, Seba K, Veloso VG, Grinsztejn B, et al. Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01441-9

BibTeX
@article{Toledo2024,
  author = {Toledo, Thainá and Oliveira, Vanessa G and Cattani, Vitória Berg and Seba, Karine and Veloso, Valdilea Gonçalves and Grinsztejn, Beatriz and Cardoso, Sandra Wagner and Torres, Thiago S and Estrela, Rita},
  title = {Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005},
  journal = {Clinical Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s40262-024-01441-9}
}
Kostenlos starten →